AACR: Affimed builds case for natural killer cell therapy
Sanofi places $75m bet with ABL on popular Parkinson’s drug target
J&J bulks up in bispecifics with $1.3bn Xencor alliance
Straight after its first cancer bispecific OK, J&J highlights two more at ASCO
Lilly bolts on cancer bispecifics with $1.6bn Merus alliance
Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO
Agreement could add to Novartis’ immuno-oncology pipeline.
Novartis buys into bispecific antibodies with Xencor deal